These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22525956)

  • 1. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
    Frazier JA; Giuliano AJ; Johnson JL; Yakutis L; Youngstrom EA; Breiger D; Sikich L; Findling RL; McClellan J; Hamer RM; Vitiello B; Lieberman JA; Hooper SR
    J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):496-505. PubMed ID: 22525956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
    Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
    Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
    Findling RL; Johnson JL; McClellan J; Frazier JA; Vitiello B; Hamer RM; Lieberman JA; Ritz L; McNamara NK; Lingler J; Hlastala S; Pierson L; Puglia M; Maloney AE; Kaufman EM; Noyes N; Sikich L
    J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):583-94; quiz 632. PubMed ID: 20494268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
    Taylor JH; Appel S; Eli M; Alexander-Bloch A; Maayan L; Gur RE; Bloch MH
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):46-52. PubMed ID: 32633541
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.
    McCLELLAN J; Sikich L; Findling RL; Frazier JA; Vitiello B; Hlastala SA; Williams E; Ambler D; Hunt-Harrison T; Maloney AE; Ritz L; Anderson R; Hamer RM; Lieberman JA
    J Am Acad Child Adolesc Psychiatry; 2007 Aug; 46(8):969-978. PubMed ID: 17667476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
    Bachman P; Jalbrzikowski M; Bearden CE
    J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):464-6. PubMed ID: 22525952
    [No Abstract]   [Full Text] [Related]  

  • 8. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
    Croarkin PE; Daskalakis ZJ
    J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):949-51. PubMed ID: 22917209
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
    Gabriel D; Jakubovski E; Taylor JH; Artukoglu BB; Bloch MH
    Psychiatry Res; 2017 Sep; 255():248-255. PubMed ID: 28595147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
    Goldberg TE; Burdick KE; McCormack J; Napolitano B; Patel RC; Sevy SM; Goldman R; Lencz T; Malhotra AK; Kane JM; Robinson DG
    Schizophr Res; 2009 Feb; 107(2-3):262-6. PubMed ID: 19042105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
    J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
    Harvey PD; Napolitano JA; Mao L; Gharabawi G
    Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.